Palvella Therapeutics stock price target raised to $97 by TD Cowen
PositiveFinancial Markets

Palvella Therapeutics has received a significant boost as TD Cowen raises its stock price target to $97. This positive adjustment reflects growing confidence in the company's potential and could attract more investors, highlighting the optimism surrounding its future prospects.
— via World Pulse Now AI Editorial System
